caffo2def.ppt [modalità compatibilità]...100% M1 1 beyond pelvisand vertebralcolumn) Appendicular...
Transcript of caffo2def.ppt [modalità compatibilità]...100% M1 1 beyond pelvisand vertebralcolumn) Appendicular...
Di b 2012Dicembre 2012
• P.A. 65 anni• In terapia anti‐ipertensiva da 4 anni (sartanico)(sartanico)
• Non ha mai eseguito il PSA• Da qualche mese dolore alla spalla sx che sia accentua coi movimentiaccentua coi movimenti
• Si rivolge al curante che prescrive Rx standardSi rivolge al curante che prescrive Rx standard
Di b 2012Dicembre 2012
• All’Rx: area ovalare di addensamento di circa 3 tibil l i d i llcm compatibile con lesione secondaria alla
testa omerale• Scintigrafia ossea: tre lesioni (omero sx, L3, IV
)• Scintigrafia ossea: cinque lesioni (omero sx, D2 D12 L3 IV costa sx)costa sx)
• PSA = 43
D2, D12, L3, IV costa sx)
PSA = 43• Visita urologica con biopsia: GS 9 (5+4)• TAC addome: negativa
O i i t ti hOpzioni terapeutiche
• AA per 4 settimane + ADT• AA per 4 settimane + ADT+ ac zoledronico (o denosumab)denosumab)
• BAT• BAT + ac zoledronico (o denosumab)• Ac zoledronico (o denosumab)
O i i t ti hOpzioni terapeutiche
• AA per 4 settimane + ADT• AA per 4 settimane + ADT+ ac zoledronico (o denosumab)denosumab)
• BAT• BAT + ac zoledronico (o denosumab)• Ac zoledronico (o denosumab)• ADT + Docetaxel• ADT + Docetaxel
Th hi tThe history
• Feb 2013: GETUG‐15 publication
mOS HR P value
ADT+D 58.9 1.01 0.955
ADT 54.2 ‐‐ ‐‐
Th hi tThe history
• Feb 2013: GETUG‐15 publication
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation• Feb 2015: updated GETUG 15 presentation• Feb 2015: updated GETUG‐15 presentation
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation• Feb 2015: updated GETUG 15 presentation• Feb 2015: updated GETUG‐15 presentation
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation• Feb 2015: updated GETUG 15 presentation• Feb 2015: updated GETUG‐15 presentation• June 2015: STAMPEDE (arm C) presentation( ) p
STAMPEDE t i lSTAMPEDE trial
Newly diagnosed high risk patients T3/4 N0 M0 with: – At least two of:PSA≥40ng/ml or Gleason sum score 8‐10g/– And intention to treat with radical radiotherapy (unless there is a contra‐
indication; exemption must be sought in advance of consent, after discussion with MRC CTU)CTU)
Newly diagnosed metastatic or nodal disease– Stage Tany N+ M0 or Tany Nany M+
Previously treated relapsing patients with either– PSA ≥ 4ng/ml and rising with doubling time < 6 months– PSA ≥ 20ng/ml– N+– M+
STAMPEDES i h i d i iSystemic Therapy in Advancing or Metastatic Prostate cancer:
Evaluation of Drug Efficacy
Th hi tThe history
• Feb 2013: GETUG‐15 publication• June 2014: first CHAARTED presentation• Feb 2015: updated GETUG 15 presentation• Feb 2015: updated GETUG‐15 presentation• June 2015: STAMPEDE (arm C) presentation( ) p
CHAARTED GETUG 15 STAMPEDE (all) STAMPEDE (M1)
Recruitment period 2006‐2012 2004‐2008 2005‐2013 2005‐2013
i 90 38 6 08Patients 790 385 1776 1087
Median age 64 yrs 64 yrs 65 yrs NR
M t 100% 100% 61% 100%Mets 100% 100% 61% 100%
Visceral 16% 13% NR NR
% h h l66% high volume•Visceral mets and/or•≥ 4 bone mets (at last 22% high risk
(Glass definition)39%M0/61% M1
100% M1
1 beyond pelvis and vertebral column)
(Glass definition)Appendicular Disease
Logrank = 42.34p<0 001
= 1. Present= 0. Absent
HR‐1
61% M1
CHAARTED GETUG 15 ( )
STAMPEDE (all) STAMPEDE (M1)
p<0.001HR 1n=155
PerformanceStatus ≥1<1
Logrank = 15.42(updated)
Follow‐up 29 m 82.9 m NR NR
PSA/ li i l PFS 21 15 23 13 37 21 NR
gp<0.001
≥65<65PSA
L k 7 66≥8<8
Gleason’sSurnL k 5 65PSA/clinical PFS 21 m vs 15 m
HR 0.5623 m vs 13 m
HR 0.7037 m vs 21 mHR 0.73
NR
OS ADT+D vs ADT 57 m vs 44 m 61 m vs 46 m 77 m vs 67 mos 65 m vs 43 m
Logrank = 7.66p=0.071
HR=3.0n=167
HR=1.75n=42
Logrank = 5.65p=0.03
HR=2.01n=96
HR=1.28n=60
OS ADT D vs ADT 57 m vs 44 m HR 0.61
p = 0.0003
61 m vs 46 m HR 0.90p = 0.44
77 m vs 67 mosHR 0.76p = 0.003
65 m vs 43 mHR 0.73p = 0.002
Group 1 Group 2 Group 3
% h h l66% high volume•Visceral mets and/or•≥ 4 bone mets (at last 22% high risk
(Glass definition)100% M1
1 beyond pelvis and vertebral column)
(Glass definition)
CHAARTED GETUG 15 ( )
STAMPEDE (all) STAMPEDE (M1)(updated)
Follow‐up 29 m 82.9 m NR NR
PSA/ li i l PFS 21 15 23 13 37 21 NRPSA/clinical PFS 21 m vs 15 mHR 0.56
23 m vs 13 mHR 0.70
37 m vs 21 mHR 0.73
NR
OS ADT+D vs ADT 57 m vs 44 m 61 m vs 46 m 77 m vs 67 mos 65 m vs 43 mOS ADT D vs ADT 57 m vs 44 mHR 0.61
p = 0.0003
61 m vs 46 mHR 0.90p = 0.44
77 m vs 67 mosHR 0.76p = 0.003
65 m vs 43 mHR 0.73p = 0.002
% h h l66% high volume•Visceral mets and/or•≥ 4 bone mets (at last 22% high risk
(Glass definition)100% M1
1 beyond pelvis and vertebral column)
(Glass definition)
CHAARTED GETUG 15 ( )
STAMPEDE (all) STAMPEDE (M1)(updated)
Follow‐up 29 m 82.9 m NR NR
PSA/ li i l PFS 21 15 23 13 37 21 NRPSA/clinical PFS 21 m vs 15 mHR 0.56
23 m vs 13 mHR 0.70
37 m vs 21 mHR 0.73
NR
OS ADT+D vs ADT 57 m vs 44 m 61 m vs 46 m 77 m vs 67 mos 65 m vs 43 mOS ADT D vs ADT 57 m vs 44 m HR 0.61
p = 0.0003
61 m vs 46 m HR 0.90p = 0.44
77 m vs 67 mosHR 0.76p = 0.003
65 m vs 43 mHR 0.73p = 0.002
Post‐progression treatmentsPost progression treatments
Experimental arm Control arm
GETUG15 CHAARTED STAMPEDE GETUG15 CHAARTED STAMPEDE
Docetaxel 28% 12% 14% 62% 33% 41%
Abiraterone/Enzalutamide
15%* 23% 35% 15%* 20% 30%/ n alutamide
* Enrolled in clinical trials vs placebo
Sid ff tSide effectsTAX 327 GETUG CHAARTED STAMPEDE
Anemia 5 2 1 NR
Thrombocytopenia 1 <1 ‐ NR
Neutropenia 32 32 12 12
Febrile neutropenia 3 7 6 12
Fatigue 5 7 4 NR
P t i th iPost‐progression therapies
Chemotherapy 198py
Bisphosphonate 95
Abiraterone 83
90 ti t 50 43 27 22 15 3 25090 patients 50 43 27 22 15 3 250
277 patients do not report receiving any ‘curative’ therapies post-failure-free survival event. The majority of patients reporting being on chemotherapy are on docetaxel
• Chemo is the new standard for a quote of M1 HSPC ( l ti it i id tifi ti iHSPC (selection criteria identification is a challenge)g )
• The adoption of CHAARTED strategy could• The adoption of CHAARTED strategy could impact on intermittent ADT diffusion